# EDGAR Filing Document

**Accession Number:** 0001813814
**File Stem:** 0001193125-23-070165
**Filing Date:** 2023-3
**Character Count:** 36770
**Document Hash:** 50c9ffff7587053f507d7c77babb2888
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-23-070165.hdr.sgml**: 20230314

**ACCESSION NUMBER**: 0001193125-23-070165

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 5

**FILED AS OF DATE**: 20230314

**DATE AS OF CHANGE**: 20230314

**EFFECTIVENESS DATE**: 20230314

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Mind Medicine (MindMed) Inc.
- **CENTRAL INDEX KEY:** 0001813814
- **STANDARD INDUSTRIAL CLASSIFICATION:** MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** A1
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-270526
- **FILM NUMBER:** 23731248

**BUSINESS ADDRESS:**
- **STREET 1:** 1166 ALBERNI STEET
- **STREET 2:** SUITE 1604
- **CITY:** VANCOUVER
- **STATE:** A1
- **ZIP:** V6E 3Z3
- **BUSINESS PHONE:** (212) 220-6633

**MAIL ADDRESS:**
- **STREET 1:** 1166 ALBERNI STEET
- **STREET 2:** SUITE 1604
- **CITY:** VANCOUVER
- **STATE:** A1
- **ZIP:** V6E 3Z3

**As filed with the Securities and Exchange Commission on March 14, 2023** 

**Registration No. 333-** 

------

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549** 

------

**FORM S-8** 

**REGISTRATION STATEMENT** 

***UNDER***

***THE SECURITIES ACT OF 1933***

------

## MIND MEDICINE (MINDMED) INC.
**(Exact name of registrant as specified in its charter)** 

------

---

| | |
|:---|:---|
| **British Columbia, Canada** | **98-1582438** |
| **(State or other jurisdiction of**<br> **incorporation or organization)** | **(I.R.S. Employer**<br> **Identification Number)** |
| **One World Trade Center, Suite 8500**<br> **New York, New York** | **10007** |
| **(Address of Principal Executive Offices)** | **(Zip Code)** |

---

**MIND MEDICINE (MINDMED) INC. STOCK OPTION PLAN** 

**MIND MEDICINE (MINDMED) INC. PERFORMANCE AND RESTRICTED SHARE UNIT PLAN** 

**(Full titles of the plans)** 

------

**Robert Barrow** 

**Chief Executive Officer** 

**Mind Medicine (MindMed) Inc.** 

**One World Trade Center, Suite 8500** 

**New York, New York 10007** 

**(650) 208-2454** 

**(Name, address, including zip code, and telephone number, including area code, of agent for service)** 

------

***Copies to:***

---

| | |
|:---|:---|
| **Mark Ballantyne**<br> **Christian Plaza**<br> **Dayne Brown**<br> **Cooley LLP**<br> **11951 Freedom Drive**<br> **Reston, Virginia 20190**<br> **(703) 456-8000** | **Trevor Scott**<br> **Osler, Hoskin & Harcourt LLP**<br> **Suite 1700, Guinness Tower**<br> **1055 West Hastings Street**<br> **Vancouver, British Columbia, Canada V6E 2E9**<br> **(778) 785-3000** |

---

------

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ☐ | Accelerated filer | ☐ |
| Non-accelerated filer | ☒ | Smaller reporting company | ☒ |
|  |  | Emerging growth company | ☒ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

------

**PART I** 

**INFORMATION REQUIRED IN THE SECTION 10(A) PROSPECTUS** 

The information specified in Item 1 and Item 2 of Part I of Form S-8 is omitted from this Registration Statement. The documents containing the information specified in in Part I of Form S-8 will be delivered to the participants in the plans covered by this Registration Statement as specified by Rule 428(b)(1) under the Securities Act of 1933, as amended (the "***Securities Act***").

**PART II** 

**INFORMATION REQUIRED IN THE REGISTRATION STATEMENT** 

---

| | |
|:---|:---|
| **ITEM 3.** | **INCORPORATION OF DOCUMENTS BY REFERENCE**  |

---

The following documents filed by Mind Medicine (MindMed) Inc. (the "***Registrant***") with the Securities and Exchange Commission (the "***Commission***") are incorporated by reference into this Registration Statement:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a) The Registrant's Annual Report on [Form 10-K](http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1813814/000095017023007053/mnmd-20221231.htm) for the fiscal year ended December 31, 2022, filed with the Commission on March 9, 2023;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b) The Registrant's Current Reports on Form 8-K, filed with the
Commission on [January 9, 2023](http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1813814/000119312523004781/d444623d8k.htm) and [March 13, 2023](http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1813814/000119312523068454/d456950d8k.htm) ; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c) The description of the Registrant's ordinary shares which is contained in the Registrant's
Registration Statement on [Form 8-A](http://www.sec.gov/Archives/edgar/data/1813814/000110465921053876/tm2112540d1_8a12b.htm) filed on April 22, 2021 (File No 001-40360) under the Securities Exchange Act of 1934, as amended (the "  ***Exchange Act*** "), as updated by [Exhibit 4.1](http://www.sec.gov/Archives/edgar/data/1813814/000095017023007053/mnmd-ex4_1.htm) to the Registrant's Annual Report on [Form 10-K](http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1813814/000095017023007053/mnmd-20221231.htm) for the fiscal year ended December 31, 2022, including any amendment or report filed for the purpose of updating such description.

All documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act after the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference in this Registration Statement and to be part hereof from the date of filing of such documents; provided, however, that documents or portions thereof that are furnished and not filed in accordance with the rules of the Commission shall not be deemed incorporated by reference into this Registration Statement. Any statement in a document incorporated or deemed to be incorporated by reference in this Registration Statement will be deemed to be modified or superseded to the extent that a statement contained in this Registration Statement or in any other later filed document that also is or is deemed to be incorporated by reference modifies or supersedes such statement. Any such statement so modified or superseded will not be deemed, except as so modified or superseded, to be a part of this Registration Statement.

---

| | |
|:---|:---|
| **ITEM 4.** | **DESCRIPTION OF SECURITIES**  |

---

Not applicable.

---

| | |
|:---|:---|
| **ITEM 5.** | **INTERESTS OF NAMED EXPERTS AND COUNSEL**  |

---

Not applicable.

---

| | |
|:---|:---|
| **ITEM 6.** | **INDEMNIFICATION OF DIRECTORS AND OFFICERS**  |

---

The Registrant is subject to the provisions of Part 5, Division 5 of the Business Corporations Act (*British Columbia*) (the "***Act***"), and the indemnification provisions set forth in the Registrant's amended and restated articles (the "***Articles***"). The Registrant has also entered into indemnity agreements with certain of its directors and executive officers which provide its directors and executive officers with contractual rights to indemnification and, in some cases, expenses advancement in any action or proceedings arising out of their services as one of its directors and executive officers or as a director or executive officer of any other company or enterprise to which the person provides services at the Registrant's request.

------

Under the Registrant's Articles and Section 160 of the Act, subject to Section 163 of the Act, the Registrant may:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a) indemnify an individual who:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;i. is or was a director or officer of the Registrant,

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ii. is or was a director or officer of another corporation (A) at a time when such corporation is or was an
affiliate of the Registrant; or (B) at the Registrant's request, or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;iii. at the Registrant's request, is or was, or holds or held a position equivalent to that of, a director or
officer of a partnership, trust, joint venture or other unincorporated entity,

including, subject to certain limited exceptions, the heirs and personal or other legal representatives of that individual (collectively, an "***eligible party***"), against all eligible penalties, defined below, to which the eligible party is or may be liable; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b) after final disposition of an eligible proceeding, pay the expenses actually and reasonably incurred by an
eligible party in respect of that proceeding, where:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;i. "  ***eligible penalty***" means a judgment, penalty or fine awarded or imposed in, or an
amount paid in settlement of, an eligible proceeding,

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ii. "  ***eligible proceeding***" means a proceeding in which an eligible party or any of the heirs
and personal or other legal representatives of the eligible party, by reason of the eligible party being or having been a director or officer of, or holding or having held a position equivalent to that of a director or officer of, the Registrant or
an associated corporation (A) is or may be joined as a party, or (B) is or may be liable for or in respect of a judgment, penalty or fine in, or expenses related to, the proceeding,

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;iii. "  ***expenses***" includes costs, charges and expenses, including legal and other fees, but
does not include judgments, penalties, fines or amounts paid in settlement of a proceeding, and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;iv. "  ***proceeding***" includes any legal proceeding or investigative action, whether current,
threatened, pending or completed.

Under the Registrant's Articles, the Registrant may also indemnify any employee, agent or representative of the Registrant subject to any restrictions under the Act.

Under the Registrant's articles and Section 161 of the Act, and subject to Section 163 of the Act, the Registrant must, after the final disposition of an eligible proceeding, pay the expenses actually and reasonably incurred by an eligible party in respect of that proceeding if the eligible party (a) has not been reimbursed for those expenses, and (b) is wholly successful, on the merits or otherwise, in the outcome of the proceeding or is substantially successful on the merits in the outcome of the proceeding.

Under Section 162 of the Act, and subject to Section 163 of the Act, the Registrant may pay, as they are incurred in advance of the final disposition of an eligible proceeding, the expenses actually and reasonably incurred by an eligible party in respect of the proceeding, provided that the Registrant must not make such payments unless the Registrant first receive from the eligible party a written undertaking that, if it is ultimately determined that the payment of expenses is prohibited under Section 163 of the Act, the eligible party will repay the amounts advanced.

Under Section 163 of the Act, the Registrant must not indemnify an eligible party against eligible penalties to which the eligible party is or may be liable or pay the expenses of an eligible party in respect of that proceeding under Sections 160, 161 or 162 of the Act, as the case may be, if any of the following circumstances apply:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a) if the indemnity or payment is made under an earlier agreement to indemnify or pay expenses and, at the time
that the agreement to indemnify or pay expenses was made, the Registrant was prohibited from giving the indemnity or paying the expenses by the Registrant's memorandum or articles;

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b) if the indemnity or payment is made otherwise than under an earlier agreement to indemnify or pay expenses and,
at the time that the indemnity or payment is made, the Registrant is prohibited from giving the indemnity or paying the expenses by the Registrant's memorandum or articles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c) if, in relation to the subject matter of the eligible proceeding, the eligible party did not act honestly and
in good faith with a view to the best interests of the Registrant or the associated corporation, as the case may be; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d) in the case of an eligible proceeding other than a civil proceeding, if the eligible party did not have
reasonable grounds for believing that the eligible party's conduct in respect of which the proceeding was brought was lawful.

If an eligible proceeding is brought against an eligible party by or on behalf of the Registrant or by or on behalf of an associated corporation, the Registrant must not either indemnify the eligible party under Section 160(a) of the Act against eligible penalties to which the eligible party is or may be liable, or pay the expenses of the eligible party under Sections 160(b), 161 or 162 of the Act, as the case may be, in respect of the proceeding.

Under Section 164 of the Act, and despite any other provision of Part 5, Division 5 of the Act and whether or not payment of expenses or indemnification has been sought, authorized or declined under Part 5, Division 5 of the Act, on application of the Registrant or an eligible party, the court may do one or more of the following:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a) order the Registrant to indemnify an eligible party against any liability incurred by the eligible party in
respect of an eligible proceeding;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b) order the Registrant to pay some or all of the expenses incurred by an eligible party in respect of an eligible
proceeding;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c) order the enforcement of, or any payment under, an agreement of indemnification entered into by the Registrant;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d) order the Registrant to pay some or all of the expenses actually and reasonably incurred by any person in
obtaining an order under Section 164 of the Act; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;e) make any other order the court considers appropriate.

Section 165 of the Act provides that the Registrant may purchase and maintain insurance for the benefit of an eligible party or the heirs and personal or other legal representatives of the eligible party against any liability that may be incurred by reason of the eligible party being or having been a director or officer of, or holding or having held a position equivalent to that of a director or officer of, the Registrant or an associated corporation. Under the Registrant's Articles, the Registrant may also purchase and maintain insurance for the benefit of any person (or his or her heirs or legal personal representatives) who:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a) is or was a director, alternate director, officer, employee or agent of the Registrant;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b) is or was a director, alternate director, officer, employee or agent of another corporation at a time when such
corporation is or was an affiliate of the Registrant;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c) at the Registrant's request, is or was, a director, alternate director, officer, employee or agent of a
corporation or of a partnership, trust, joint venture or other unincorporated entity; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d) at the Registrant's request, is or was, or holds or held a position equivalent to that of, a director,
alternate director or officer of a partnership, trust, joint venture or other unincorporated entity, against any liability incurred by him or her as a director, alternate director, officer, employee or agent or person who holds or held such
equivalent position.

------

The Registrant maintains directors' and officers' liability insurance which insures directors and officers for losses as a result of claims against the directors and officers of the Registrant in their capacity as directors and officers.

Pursuant to the Registrant's Articles, the failure of a director or officer of the Registrant to comply with the Act or the Registrant's Articles does not invalidate any indemnity to which he or she is entitled under the Registrant's Articles.

Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers or persons controlling the Registrant pursuant to the foregoing provisions, the Registrant has been informed that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable.

---

| | |
|:---|:---|
| **ITEM 7.** | **EXEMPTION FROM REGISTRATION CLAIMED**  |

---

Not applicable.

---

| | |
|:---|:---|
| **ITEM 8.** | **EXHIBITS**  |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Exhibit**<br> **Number** | **Description** | **Form** | **Exhibit No.** | **Incorporated by**<br> **Reference Filing<br>Date** | **File No.** |
| &nbsp;&nbsp;&nbsp;&nbsp;4.1 | [Amended and Restated Articles of Mind Medicine (MindMed) Inc., effective as of June 30, 2022.](http://www.sec.gov/Archives/edgar/data/1813814/000119312522186293/d730734dex31.htm) | 8-K | 3.1 | June 30, 2022 | 001-40360 |
| &nbsp;&nbsp;&nbsp;&nbsp;4.2 | [Notice of Articles, Incorporated on July 26, 2010, as altered on June 30, 2022](http://www.sec.gov/Archives/edgar/data/1813814/000095017023007053/mnmd-ex3_2.htm) | 10-K | 3.2 | March 9, 2023 | 001-40360 |
| &nbsp;&nbsp;&nbsp;&nbsp;4.3 | [Form of Mind Medicine (MindMed) Inc. Common Share Certificate.](http://www.sec.gov/Archives/edgar/data/1813814/000095017023007053/mnmd-ex4_2.htm) | 10-K | 4.2 | March 9, 2023 | 001-40360 |
| &nbsp;&nbsp;&nbsp;&nbsp;5.1\* | [Opinion of Osler, Hoskin & Harcourt LLP](d482592dex51.htm). |  |  |  |  |
| 23.1\* | [Consent of KPMG LLP.](d482592dex231.htm) |  |  |  |  |
| 23.2\* | [Consent of Ernst & Young LLP.](d482592dex232.htm) |  |  |  |  |
| 23.3\* | [Consent of Osler, Hoskin & Harcourt LLP (included in Exhibit 5.1).](d482592dex51.htm) |  |  |  |  |
| 24.1\* | [Powers of Attorney (included on the signature page).](d482592ds8.htm#sig) |  |  |  |  |
| 99.1 | [Mind Medicine (MindMed), Inc. Stock Option Plan, as amended on March 7, 2023.](http://www.sec.gov/Archives/edgar/data/1813814/000095017023007053/mnmd-ex10_15.htm) | 10-K | 10.15 | March 9, 2023 | 001-40360 |
| 99.2 | [Mind Medicine (MindMed), Inc. Performance and Restricted Share Unit Plan, as amended on March 7, 2023.](http://www.sec.gov/Archives/edgar/data/1813814/000095017023007053/mnmd-ex10_16.htm) | 10-K | 10.16 | March 9, 2023 | 001-40360 |
| 99.3 | [Form of Option Agreement to Mind Medicine (MindMed) Inc. Stock Option Plan](http://www.sec.gov/Archives/edgar/data/1813814/000095017023007053/mnmd-ex10_17.htm) | 10-K | 10.17 | March 9, 2023 | 001-40360 |
| 99.4 | [Mind Medicine (MindMed), Inc. Option Plan.](http://www.sec.gov/Archives/edgar/data/1813814/000095017023007053/mnmd-ex10_2.htm) | 10-K | 10.2 | March 9, 2023 | 001-40360 |
| 99.5 | [Mind Medicine (MindMed), Inc. Performance and Restricted Share Unit Plan.](http://www.sec.gov/Archives/edgar/data/1813814/000095017022004724/mnmd-ex10_3.htm) | 10-K | 10.3 | March 9, 2023 | 001-40360 |
| 99.6 | [Form of Restricted Share Unit Grant Agreement to Mind Medicine (MindMed) Inc. Performance and Restricted Share Unit Plan.](http://www.sec.gov/Archives/edgar/data/1813814/000095017022004724/mnmd-ex10_4.htm) | 10-K | 10.4 | March 28, 2022 | 001-40360 |
| 107\* | [Filing Fee Table.](d482592dexfilingfees.htm) |  |  |  |  |

---

------

\* Filed herewith.

------

---

| | |
|:---|:---|
| **ITEM 9.** | **UNDERTAKINGS**  |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) The undersigned Registrant hereby undertakes:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) To file, during any period in which offers or sales are being made, a post-effective amendment to this
registration statement:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) to include any prospectus required by section 10(a)(3) of the Securities Act;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) to reflect in the prospectus any facts or events arising after the effective date of this registration
statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in this registration statement. Notwithstanding the foregoing, any increase or
decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of
prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the "Calculation of Registration
Fee" table in the effective registration statement; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) to include any material information with respect to the plan of distribution not previously disclosed in the
registration statement or any material change to that information in the registration statement;

*provided, however*, that paragraphs (a)(1)(i) and (a)(1)(ii) above do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the Registrant pursuant to section 13 or section 15(d) of the Exchange Act that are incorporated by reference in this registration statement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment
shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3) To remove from registration by means of a post-effective amendment any of the securities being registered which
remain unsold at the termination of the offering.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the
Securities Act, each filing of the Registrant's annual report pursuant to section 13(a) or 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan's annual report pursuant to section 15(d) of the Exchange
Act) that is incorporated by reference in this registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial
bona fide offering thereof.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors,
officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities
Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the
successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been
settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

------

**SIGNATURES** 

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of New York, State of New York, on March 14, 2023.

---

| | |
|:---|:---|
| **Mind Medicine (MindMed) Inc.** | **Mind Medicine (MindMed) Inc.** |
| By: | /s/ Robert Barrow |
|  | Robert Barrow |
|  | *Chief Executive Officer* |

---

**POWER OF ATTORNEY** 

KNOW ALL BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Robert Barrow and Schond L. Greenway, and each of them, his or her true and lawful agents, proxies and attorneys-in-fact, with full power of substitution and resubstitution, for and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this registration statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact full power and authority to do and perform each and every act and thing requisite and necessary to be done as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

---

| | | |
|:---|:---|:---|
| **Signature** | **Title** | **Date** |
| /s/ Robert Barrow<br> **Robert Barrow** | Chief Executive Officer and Director<br> (*Principal Executive Officer*) | March 14, 2023 |
| /s/ Schond L. Greenway<br> **Schond L. Greenway** | Chief Financial Officer<br> (*Principal Financial Officer*) | March 14, 2023 |
| /s/ Carrie F. Liao<br> **Carrie F. Liao, CPA** | Chief Accounting Officer<br> (*Principal Accounting Officer*) | March 14, 2023 |
| /s/ Suzanne Bruhn<br> **Suzanne Bruhn, PhD** | Director | March 14, 2023 |
| /s/ Brigid A. Makes<br> **Brigid A. Makes** | Director | March 14, 2023 |
| /s/ Roger Crystal<br> **Roger Crystal, MD** | Director | March 14, 2023 |
| /s/ Andreas Krebs<br> **Andreas Krebs** | Director | March 14, 2023 |
| /s/ Carol Vallone<br> **Carol Vallone** | Director | March 14, 2023 |

---

## Exhibit 5.1

**Exhibit 5.1** 

March 14, 2023

**Mind Medicine (MindMed) Inc.**

One World Trade Center, Suite 8500

New York, New York 10007

Dear Sirs/Mesdames:

**<u>Re: Mind Medicine (MindMed) Inc.—Registration Statement on Form S-8</u>**

We have acted as Canadian counsel to Mind Medicine (MindMed) Inc. (the "**Company**"), a company incorporated under the *Business Corporations Act* (British Columbia), in connection with the registration of up to 5,721,837 common shares, no par value per share, of the Company (the "**Common Shares**") reserved for issuance pursuant to the Mind Medicine (MindMed) Inc. Stock Option Plan, as amended on March 7, 2023 (the "**Option Plan**") and pursuant to the Mind Medicine (MindMed) Inc. Performance and Restricted Share Unit Plan, as amended on March 7, 2023 (the "**PRSU Plan**" and, collectively with the Option Plan, the "**Plans**"), pursuant to a registration statement on Form S-8 (the "**Registration Statement**") filed on March 14, 2023 with the United States Securities and Exchange Commission under the *Securities Act of 1933*, as amended, relating to the registration of the Common Shares.

We have examined the Registration Statement, the Plans, the form of Option Agreement (as defined in the Option Plan) and the form of Award Agreement (as defined in the PRSU Plan) and all such corporate and public records, statutes and regulations and have made such investigations and have reviewed such other documents as we have deemed relevant and necessary and have considered such questions of law as we have considered relevant and necessary in order to give the opinion hereinafter set forth. As to various questions of fact material to such opinions which were not independently established, we have relied upon a certificate of an officer of the Company.

In reviewing the foregoing documents and in giving this opinion, we have assumed the legal capacity of all individuals, the genuineness of all signatures, the veracity of the information contained therein, the authenticity of all documents submitted to us as originals and the conformity to authentic or original documents of all documents submitted to us as certified, conformed, electronic, photostatic or facsimile copies.

We are qualified to practice law in the Province of British Columbia and this opinion is rendered solely with respect to the laws of the Province of British Columbia and the federal laws of Canada applicable therein.

------

On the basis of the foregoing, we are of the opinion that the Common Shares have been authorized for issuance pursuant to the terms of the Option Plan and PRSU Plan, as applicable, and, when (x) issued in accordance with the terms of PRSU Plan and the applicable Award Agreement or (y) when issued and paid for in accordance with the terms of the Option Plan and the applicable Option Agreement, as applicable, the Common Shares will be validly issued, fully paid and non-assessable.

We hereby consent to the filing of this opinion as an exhibit to the Registration Statement.

Yours very truly,

*(signed) Osler, Hoskin & Harcourt LLP* 

Osler, Hoskin & Harcourt LLP

## Exhibit 23.1

**Exhibit 23.1** 

**Consent of Independent Registered Public Accounting Firm** 

We consent to the use of our report dated March 9, 2023, with respect to the consolidated financial statements of Mind Medicine (MindMed) Inc., incorporated herein by reference.

/s/ KPMG LLP

San Diego, California

March 14, 2023

## Exhibit 23.2

**Exhibit 23.2** 

Consent of Independent Registered Public Accounting Firm

We consent to the incorporation by reference in this Registration Statement on Form S-8 of our report dated March 28, 2022, with respect to the consolidated financial statements of Mind Medicine (MindMed) Inc. for the year ended December 31, 2021, included in the Annual Report on Form 10-K of Mind Medicine (MindMed) Inc. for the year ended December 31, 2022.

---

| | |
|:---|:---|
| Toronto, Canada, <br>March 14, 2023 | /s/ Ernst & Young LLP<br>Chartered Professional Accountants<br>Licensed Public Accountants |

---

## Ex-Filing

**Exhibit 107** 

**Calculation of Filing Fee Table** 

**Form S-8** 

(Form Type)

**Mind Medicine (MindMed) Inc.** 

(Exact Name of Registrant as Specified in its Charter)

<u>Table 1: Newly Registered Securities</u> 

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| &nbsp;&nbsp;&nbsp;**Security Type** | **Security**<br> **Class**<br> **Title** | **Fee<br>Calculation<br>Rule** | **Proposed**<br> **Maximum<br>Aggregate**<br> **Offering**<br> **Price** | **Fee**<br> **Rate** | **Amount of<br>Registration<br>Fee** |
| &nbsp;&nbsp;&nbsp;Equity | Common shares, no par value per share | Other2138872<sup>(2)(3)</sup> $19.17<sup>(7)</sup> | $41002176.24 | 0.00011020 | $4518.44 |
| &nbsp;&nbsp;&nbsp;Equity | Common shares, no par value per share | Other1458997<sup>(4)(5)</sup> $3.15<sup>(8)</sup> | $4595840.55 | 0.00011020 | $506.46 |
| &nbsp;&nbsp;&nbsp;Equity | Common shares, no par value per share | Other2123968<sup>(6)</sup> $3.15<sup>(8)</sup> | $6690499.20 | 0.00011020 | $737.29 |
| &nbsp;&nbsp;&nbsp;**Total Offering Amounts** | &nbsp;&nbsp;&nbsp;**Total Offering Amounts** | &nbsp;&nbsp;&nbsp;**Total Offering Amounts** | $52288515.99 |  | $5762.19 |
| &nbsp;&nbsp;&nbsp;**Total Fee Offsets** | &nbsp;&nbsp;&nbsp;**Total Fee Offsets** | &nbsp;&nbsp;&nbsp;**Total Fee Offsets** |  |  |  |
| &nbsp;&nbsp;&nbsp;**Net Fee Due** | &nbsp;&nbsp;&nbsp;**Net Fee Due** | &nbsp;&nbsp;&nbsp;**Net Fee Due** |  |  | $5762.19 |

---

(1) Pursuant to Rule 416(a) of the Securities Act of 1933, as amended (the "  ***Securities Act*** "), this Registration Statement shall also cover any additional shares of Registrant's common shares, no par value per share (the "  ***Common Shares*** "), that become issuable under the Mind Medicine (MindMed)
Inc. Stock Option Plan (the "  ***Option Plan***") and the Mind Medicine (MindMed) Inc. Performance and Restricted Share Unit Plan (the "  ***PRSU Plan***" and together with the Option Plan, the
"  ***Plans***") by reason of any share dividend, share split, recapitalization or other similar transaction that results in an increase in the number of outstanding Common Shares.

(2) Represents Common Shares reserved for issuance pursuant to outstanding stock option awards under
the Option Plan as of the date of this Registration Statement.

(3) Pursuant to the Option Plan, any shares subject to outstanding options granted under the Option Plan that are
forfeited, surrendered, cancelled or otherwise terminated or expire without being exercised will become available for future issuance pursuant to the Option Plan.

(4) Represents Common Shares reserved for issuance pursuant to outstanding restricted share unit awards under the
PRSU Plan as of the date of this Registration Statement.

(5) Pursuant to the terms of the PRSU Plan, any shares subject to outstanding awards granted under the PRSU Plan
that: (i) vested and redeemed; or (ii) forfeited, surrendered, cancelled or otherwise terminated or expire without delivery of the shares, will become available for future issuance pursuant to the PRSU Plan.

(6) Represents Common Shares reserved for future issuance under the Plans as of the date of this Registration
Statement. As of the any date of grant under the Plans, the aggregate number of shares available for issuance under any Share Compensation Arrangements (as defined in the Plans and which defined term includes the Plans) is 15% of the Common Shares
issued and outstanding, subject to adjustment as described in the Plans.

(7) Estimated solely for the purpose of calculating the amount of the registration fee pursuant to Rule 457(h)
promulgated under the Securities Act. The proposed maximum offering price per share and the proposed maximum aggregate offering price are calculated using the weighted-average exercise price for such Common Shares. The amount is based on weighted
average exercise price of CAD $26.51 (US $19.17) for options granted under the Option Plan outstanding as of the date of this Registration Statement, which was converted into U.S. dollars based on the average exchange rate on March 10, 2023, as
reported by the Bank of Canada, for the conversion of Canadian dollars into U.S. dollars of CAD $1.00 per US $0.7231.

(8) Estimated solely for the purpose of calculating the amount of the registration fee pursuant to Rule 457(h)
promulgated under the Securities Act. The proposed maximum offering price per share and the proposed maximum aggregate offering price are based upon $3.15, which is the average of the high and low prices of the Registrant's Common Shares as
reported on the Nasdaq Capital Market on March 10, 2023.